M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”.

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis – JAMA

Editorial: IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19: Who, When, and How? – JAMA

Commentaries: Interleukin-6 antagonists improve outcomes in hospitalised COVID-19 patients – King’s College London AND WHO advises 2 monoclonal antibodies for severe COVID – CIDRAP

Commentary on Twitter (thread – click for more)

https://twitter.com/msh_manu/status/1412473073715056645